6885 — BRIM Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- TWD3.08bn
- TWD1.24bn
- TWD0.02m
Annual cashflow statement for BRIM Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -97 | -105 | -274 | -688 | -315 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -64.8 | 21.8 | 97.2 | 50.7 | 20.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 30.9 | -32.7 | 1.24 | 35 | 6.74 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -127 | -113 | -172 | -597 | -279 |
| Capital Expenditures | -0.366 | -0.782 | -1.21 | -3.7 | -80 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -140 | 119 | 23.8 | -748 | -585 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -140 | 119 | 22.6 | -751 | -665 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2.49 | 311 | 587 | 1,458 | 499 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -264 | 317 | 438 | 110 | -445 |